Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Global Health Ventures has signed a contract with a FDA approved, GMP licensed pharmaceutical manufacturing company Confab for the production of the company's lead therapeutic drug for sexual enhancement X-Excite for all the clinical trials and marketing.
Subscribe to our email newsletter
Confab is a Montreal-based pharmaceutical manufacturing company with licenses from both FDA and European regulatory bodies, as well as certain Asian countries to manufacture drugs for human use.
Global Health Ventures has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route.
In human studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route.
X-Excite has completed clinical development in Europe.
The final formulation of the X-Excite drug, which has similar pharmaceutical ingredient as the Pfizer drug Viagra, is now completed and can be produced in large volume.
Global Health Ventures’ ‘Relax-B’ for anxiety is also under development in Canada.
The company plans to use the same technology to deliver a number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects.
These include stress, sleeping disorders, pain killers, anti-allergy medications, heart and lung medication, migraine and addiction replacement therapies.